Summit Therapeutics PLC | Income Statement
Fiscal year is February-January. All values GBP Thousands.
2014
2015
2016
2017
2018
2019
Sales/Revenue
1,375.00
1,169.00
592.00
2,317.00
25,419.00
43,012
Cost of Goods Sold (COGS) incl. D&A
26.00
-
-
-
-
-
Gross Income
1,349.00
-
-
-
-
-
SG&A Expense
8,527.00
14,917.00
22,080.00
26,638.00
38,295.00
50,072
EBIT
7,178.00
13,781.00
-
24,323.00
13,122.00
8,198
Unusual Expense
-
-
2,611.00
-
508.00
1,416
Non Operating Income/Expense
440.00
1,030.00
233.00
1,395.00
1,398.00
14,308
Pretax Income
6,729.00
12,700.00
23,239.00
25,710.00
10,916.00
4,698
Income Tax
636.00
1,337.00
3,102.00
4,339.00
3,785.00
2,829
Consolidated Net Income
6,093.00
11,363.00
20,137.00
21,371.00
7,131.00
7,527
Net Income
6,093.00
11,363.00
20,137.00
21,371.00
7,131.00
7,527
Net Income After Extraordinaries
6,093.00
11,363.00
20,137.00
21,371.00
7,131.00
7,527
Net Income Available to Common
6,093.00
11,363.00
20,137.00
21,371.00
7,131.00
7,527
EPS (Basic)
0.30
0.29
0.34
0.35
0.11
0.09
Basic Shares Outstanding
20,509.60
39,599.20
59,102.30
61,548.60
65,434.30
85,702
EPS (Diluted)
0.30
0.25
0.30
0.31
0.11
0.09
Diluted Shares Outstanding
20,509.60
44,850.10
66,108.60
68,932.00
65,434.30
86,144
EBITDA
7,152.00
13,748.00
20,843.00
24,265.00
12,876.00
7,060
Other Operating Expense
-
-
645.00
56.00
-
-
Non-Operating Interest Income
9.00
51.00
30.00
8.00
3,096.00
4
About Summit Therapeutics
View Profile
